Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.19
Views: 661
Rating:

Professor Jean-Yves Blay and Professor Florence Duffaud

Bone sarcomas present a rare, heterogenous group of tumour types that include osteosarcoma. Although locoregional disease can often be treated effectively, osteosarcoma is difficult to address in the metastatic setting.

The REGOBONE trial w\s a set of phase II trials exploring the effect of the tyrosine kinase inhibitor regorafenib across different bone sarcomas. This session looks specifically at the osteosarcoma cohort, and evaluates the potential use of regorafenib in future treatment of metastatic osteosarcoma.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

To earn CME credits and discover further publication to practice sessions, please visit Oncology knowledge into practice.

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation